Prostate cancer (PCa) is one of the most commonly diagnosed urological malignancies. However, there are limited therapies for PCa patients who develop biochemical recurrence after androgen deprivation therapy (ADT). In the present study, we investigated the therapeutic efficacy and mechanism of α-Viniferin (KCV), an oligostilbene of trimeric resveratrol, against human PCa cells and found that it markedly inhibited the proliferation of LNCaP, DU145, and PC-3 cancer cells in a time- and dose-dependent manner, and had a strong cytotoxicity in non-androgen-dependent PCa cells. In addition, KCV inhibited AR downstream expression in LNCaP cells, and inhibited activation of GR signaling pathway in DU145 and PC-3. Further investigation indicated that KCV could induce cancer cell apoptosis through AMPK-mediated activation of autophagy, and inhibited GR expression in castration-resistant prostate cancer(CRPC). These findings suggest that KCV may prove to be a novel and effective therapeutic agent for the treatment of CRPC.
α-Viniferin Autophagy Prostate cancer Glucocorticoid receptor AMPK
This is a preview of subscription content, log in to check access.
This work was supported by grants from the National Natural Science Foundation of China (No. 81572525; No. 81170637).
Compliance with ethical standards
Conflict of interest
There is no conflict of interest in this manuscript.
Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2016; 71:618.CrossRefPubMedGoogle Scholar
Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol Off. 2008;26:1148.CrossRefGoogle Scholar
Szekeres T, Fritzer-Szekeres M, Saiko P, et al. Resveratrol and resveratrol analogues—structure—activity relationship. Pharm Res-Dordr. 2010;27:1042–8.CrossRefGoogle Scholar
Wang TT, Hudson TS, Wang TC, et al. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis. 2008 29: 2001–10.CrossRefPubMedPubMedCentralGoogle Scholar
Ferruelo A, Romero I, Cabrera PM, et al. Effects of resveratrol and other wine polyphenols on the proliferation, apoptosis and androgen receptor expression in LNCaP cells. Actas Urol Esp. 2014;38:397–404.CrossRefPubMedGoogle Scholar
Xie N, Cheng H, Lin D, et al. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer. 2015;136:E27–38.CrossRefGoogle Scholar
Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155:1309–22.CrossRefPubMedPubMedCentralGoogle Scholar
Høyer-Hansen M, Jäättelä M. AMP-activated protein kinase: a universal regulator of autophagy?. Autophagy. 2007; 3:381–3.CrossRefPubMedGoogle Scholar
Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol Off. 2011;29:3651–8.CrossRefGoogle Scholar
Wright AP, Zilliacus J, Mcewan IJ, et al. Structure and function of the glucocorticoid receptor. J Steroid Biochem Mol Biol. 1993;47:11.CrossRefPubMedGoogle Scholar
Sahu B, Laakso M, Pihlajamaa P, et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res. 2013;73:1570–80.CrossRefPubMedGoogle Scholar
Isikbay M, Otto K, Kregel S, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014;5:72.CrossRefPubMedPubMedCentralGoogle Scholar
Lee MH, Kundu JK, Keum YS, et al. Resveratrol inhibits IL-6-induced transcriptional activity of AR and STAT3 in human prostate cancer LNCaP-FGC cells. Biomol Ther (Seoul). 2014; 22:426–30.Google Scholar
Mitani T, Harada N, Tanimori S, et al. Resveratrol inhibits hypoxia-inducible factor-1 alpha-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer. J Nutr Sci Vitaminol (Tokyo). 2014; 60:276–82.CrossRefGoogle Scholar
Hardie DG. AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. Curr Opin Cell Biol. 2015;33:1–7.CrossRefPubMedGoogle Scholar
Ratman D, Mylka V, Bougarne N, et al. Chromatin recruitment of activated AMPK drives fasting response genes co-controlled by GR and PPARα. Nucleic Acids Res. 2016;44:10539–53.CrossRefPubMedPubMedCentralGoogle Scholar
Vergis R, Corbishley CM, Norman AR, et al., Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol. 2008; 9:342–51.CrossRefPubMedGoogle Scholar